UPDATE: Piper Jaffray Raises PT on Amedisys on Rebasing Overhang Nearing An End

In a report published on Tuesday, Piper Jaffray analyst Kevin K. Ellich raised the price target on Amedisys (NASDAQ: AMED ) from $8 to $12 and maintained a rating of Neutral. In the report, Piper Jaffray stated, "We believe shares of AMED could trade higher over the next few weeks